BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada. Show more
Location: Bellevue Centre, West Vancouver, BC, V7T 2X1, Canada | Website: https://briacell.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
13.84M
52 Wk Range
$0.35 - $9.82
Previous Close
$2.07
Open
$2.02
Volume
1,573,945
Day Range
$1.98 - $2.10
Enterprise Value
6.987M
Cash
12.46M
Avg Qtr Burn
-6.018M
Insider Ownership
7.33%
Institutional Own.
10.88%
Qtr Updated
04/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Bria-IMT™ (SV-BR-1-GM) Details Breast cancer | Phase 3 Data readout | |
Bria-OTS™ + tislelizumab Details Breast cancer, Cancer | Phase 1/2 Data readout | |
Bria-PROS+ Details Cancer, Prostate cancer | IND Submission |